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Opportunistic Testing: 
The Death of Informed Consent? 
Dena S. Davis† 
Abstract 
This Article focuses on one aspect of prenatal diagnosis: noninvasive 
prenatal diagnosis, particularly the detection of Trisomy 21 (Down 
Syndrome) through a simple test of maternal blood. Although I discuss 
issues salient to this particular test, I place it in the context of  
“opportunistic” testing generally. It is my view that opportunistic testing 
presents the most serious challenge to patient autonomy we are facing in 
the twenty-first century. In this Article, I will explain what I mean by 
opportunistic testing1 and consider three different examples of how it 
threatens informed consent: (1) Prostate-Specific Antigen (PSA)  
screening, (2) newborn screening, and (3) prenatal diagnosis of maternal 
blood tests for fetal anomalies. 
Contents 
I.  Opportunistic Testing ......................................................................... 36 
II.  PSA Screening ........................................................................................ 37 
III.  Newborn screening ............................................................................... 41 
IV.  Noninvasive Prenatal Diagnosis ....................................................... 49 
V.  Conclusion ............................................................................................... 54 
 
 
† Presidential Endowed Chair in Health, Humanities/Social Sciences, Lehigh 
University. B.A., Marlboro College; J.D., University of Virginia; Ph.D., 
University of Iowa. I wish to thank the organizers of this Symposium for 
the opportunity to explore my ideas on these issues, and to PennCIGHT 
(University of Pennsylvania Center for the Integration of Genetic 
Healthcare Technologies) for the opportunity to present this topic to a 
critical audience. This work was partially supported by PennCIGHT 
through grant P50HG004487 from the National Human Genome Research 
Institute at the National Institutes of Health. Some of this material has 
appeared in The Ethics Forum at the University of Montreal. 
1. In this Article, I use the terms “testing” and “screening” interchangeably 
because my three examples encompass both activities. Technically, 
however, screening describes evaluation of people who have no symptoms, 
to uncover a possible problem or risk factor; testing is part of a diagnostic 
evaluation in response to a symptom. In genetic medicine, screening usually 
describes a wide program that captures a broad population, while testing 
can target a small population or single person known to be at higher risk. 
Often the same modality (e.g., a mammogram) can be used as a screen or 
as a diagnostic test. 
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I. Opportunistic Testing 
Opportunistic testing or screening is medical testing that makes use 
of an “opportunity” engendered by some other test or modality to which 
the patient2 is accustomed or has already given consent. The opportunity 
could be as simple as the patient presenting herself for some other 
reason, as in screening asymptomatic patients for an STD such as 
chlamydia.3 In this context, the term opportunistic always implies 
“piggybacking” one intervention onto another and thus exploiting an 
opportunity. It does not necessarily imply lack of transparency. An 
opportunistic intervention can be an obviously different event, as when 
patients in a general practice waiting room who had made appointments 
for complaints unrelated to depression were screened for depression with 
their informed consent.4  
Because opportunistic interventions are, by definition, performed on 
patients who are presenting for a different reason, they are often associ-
ated with preventive care.5 As prevention becomes an increasingly 
important medical concept and recommendations for preventive 
measures grow exponentially, some critics are beginning to question the 
dilution of focus on the patient’s reason for coming to the medical 
setting and the imposition of risk information the patient may not want. 
As one commentator notes, “once information about medical risk has 
been passed on to a person . . . it cannot be retracted. Respect for 
autonomy should therefore also honour the person’s right not to be 
opportunistically confronted with knowledge about biomedical risks that 
are unrelated to his or her reasons for seeing the doctor.”6 
This Article focuses on a particular subset of opportunistic testing, 
namely tests done on a blood sample. In this case, the blood sample is 
drawn for an established purpose and then one or more extra tests are 
added. From the patient’s perspective, the intervention (a heel prick or 
blood draw) is exactly the same, making it easy for a medical profession-
al to add extra tests without the patient’s consent or knowledge. If the 
 
2. I dislike the word “patient” for many reasons, not least its implication of 
passivity. Nonetheless, there seems no better term. I prefer the locus of 
control implied by “health care consumer” or even “client,” but those 
terms do not capture the long history of the doctor/patient relationship 
from which bioethics draws. 
3. Cliodna A. M. McNulty et al., Barriers to Opportunistic Chlamydia 
Testing in Primary Care, 54 Brit. J. Gen. Practice 508, 508 (2004). 
4. Matthijs van den Berg et al., Cost-Effectiveness of Opportunistic Screening 
and Minimal Contact Psychotherapy to Prevent Depression in Primary 
Care Patients, 6 PLoS One, Aug. 2011, at 1, 2. 
5. Linn Getz et al., Is Opportunistic Disease Prevention in the Consultation 
Ethically Justifiable?, 327 Brit. Med. J. 498, 498 (2003). 
6. Id. at 499. 
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result is negative, the patient may never know that the test was per-
formed. 
II. PSA Screening 
Prostate-specific antigen (PSA) is a protein produced by the pros-
tate gland.7 A very small amount escapes into the bloodstream, allowing 
for simple testing by blood sample.8 PSA can be used as a screening 
device for men not known to have prostate cancer or as a test to monitor 
men who have been treated for prostate cancer.9 As H. Gilbert Welch 
writes, 
Like all other efforts to diagnose disease early, cancer screening is a 
double-edged sword. It can produce benefit: providing the opportunity 
to intervene early can reduce the number of deaths from cancer. It 
can produce harm: overdiagnosis and overtreatment. And it can do 
both at the same time. So while a strong case can be made for cancer 
screening, there are good reasons to approach it cautiously.10 
PSA screening is especially difficult to assess. On one hand, prostate 
cancer is the second most common cause of cancer death in men.11 On 
the other hand, most prostate cancer is “indolent,” causing no symptoms 
or harm.12 Most men diagnosed with prostate cancer die with the disease 
than because of it.13 A number of studies looked for prostate cancer in 
men who had died of other causes and who were unaware that they had 
prostate cancer. Forty percent of the men in their forties and 80 percent 
of men in their seventies were found to have had asymptomatic prostate 
cancer.14 A common problem with cancer screening is that it cannot 
distinguish between three categories of cancer: (1) nonprogressive or very 
slow-growing cancers for which treatment is unnecessary and even 
 
7. Nat’l Cancer Inst., Fact Sheet: Prostate-Specific Antigen (PSA) 
Test 1 (2012), http://www.cancer.gov/cancertopics/factsheet/ 
detection/Fs5_29.pdf [hereinafter PSA Fact Sheet]. 
8. See id. 
9. See id. 
10. H. Gilbert Welch et al., Overdiagnosed: Making People Sick in 
the Pursuit of Health 45 (2011). 
11. Nat’l Cancer Inst., Prostrate Cancer Screening: Significance, 
Cancer.gov, http://www.cancer.gov/cancertopics/pdq/screening/ 
prostate/HealthProfessional/page2/AllPages#2 (last updated Oct. 5, 
2012). 
12. See Welch et al., supra note 10, at 45. 
13. See id. at 47-48. 
14. Id. at 48. 
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harmful; (2) cancers that are so aggressive that treatment is pointless; 
and (3) cancers for which treatment will make a difference.15 
Treatment for prostate cancer is hardly harmless: substantial  
numbers of men who receive surgery or radiation for prostate cancer will 
experience irreversible impotence, incontinence, or both.16 The European 
Randomized Study of Screening for Prostate Cancer, which followed men 
for eleven years, found that annual PSA screening for men between the 
ages of fifty-five and sixty-nine reduced mortality from prostate cancer 
by 28 percent; but when the statistics were calculated as a function of 
Quality of Life Years, the advantage of screening disappeared. 17 Lives 
prolonged were canceled out by loss of quality of life. The study found 
that ninety-eight men would need to be screened and five cancers 
detected to prevent one death from prostate cancer.18 Of course, the 
other four men would almost certainly have received some form of 
(unnecessary) therapy with a high likelihood of being left with inconti-
nence, impotence, or both. 
All reputable sources echo the recommendation from the American 
Cancer Society that men should “have a chance to make an informed 
decision with their health care provider about whether to be screened for 
prostate cancer.”19 “This decision should be made after getting infor-
mation about the uncertainties, risks, and potential benefits of prostate 
cancer screening,” and men “should not be screened unless they have 
received this information.”20 The National Institutes of Health website 
advises that the value of PSA screening is “debated” and recommends 
that men discuss with their doctors the reasons for and against having 
the test before making a decision.21 In 2012, the independent United 
States Preventive Services Task Force (USPFTF) advised against 
routine screening for men of any age group.22 Co-Chair Michael Lefevre 
 
15. Id. at 53-54. 
16. Nat’l Cancer Inst., Prostate Cancer Treatment (PDQ): Treatment 
Option Overview, Cancer.gov, http://www.cancer.gov/cancertopics/ 
pdq/treatment/prostate/HealthProfessional/page4 (last modified Sept. 
21, 2012). 
17. Evelyn A.M. Heijnsdijk et al., Quality-of-Life Effects of Prostate-Specific 
Antigen Screening, 367 New Eng. J. Med. 595, 599 (2012). 
18. Id. at 600. 
19. Can Prostate Cancer Be Found Early?, Am. Cancer Soc’y, 
http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-
cancer-detection (last updated Sept. 4, 2012). 
20. Id. 
21. Nat’l Inst. of Health, PSA, MedlinePlus, http://www.nlm.nih.gov/ 
medlineplus/ency/article/003346.htm (last updated Sept. 22, 2012). 
22. David Mitchell, USPSTF Recommends Against PSA-based Prostate 
Cancer Screening, Am. Acad. of Family Physicians (Oct. 12, 2011, 5:00 
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explained that “for every 1,000 men treated for prostate cancer, five die 
of perioperative complications; 10-70 suffer significant complications but 
survive; and 200-300 suffer long-term problems, including urinary 
incontinence, impotence or both.23 That’s a lot of harm for a cancer that 
didn’t need to be treated in the first place.”24 Even Dr. Richard Ablin, 
who discovered PSA in 1970, wrote in 2010 that “[t]he test’s popularity 
has led to a hugely expensive public health disaster.”25 
Many older men continue to be screened despite 2008 USPFTF  
recommendations against routine PSA screening for men older than 
seventy-five.26 In fact, it is extremely common for men to be tested 
without their knowledge. The reason for that lies largely with the 
opportunistic quality of the test: men are used to having their blood 
screened at routine visits (e.g., for lipids), and physicians can piggyback 
the PSA test on top of the other tests without getting extra blood or 
performing any other action requiring explanation or permission. 
While that practice is indefensible, it is easy to imagine the  
physician’s thought process, or perhaps that of the institution. To not 
offer PSA might lead to a lawsuit down the road. To offer it with an 
appropriate discussion would take time, at least fifteen to twenty 
minutes.27 According to one study, the average office visit lasts 19.3 
minutes.28 Physicians and institutions may find it more efficient to give 
the test to everyone and save time by discussing it only in the 5 percent of 
cases when the results are problematic. 
An individual’s decision about whether to participate in PSA  
screening should not be regarded as trivial. The professional who offers a 
test carries a considerable responsibility, because informed consent 
presupposes an understanding of the limitations of the program. Every test 
carries a chance of misclassification of disease and false positive results 
that can lead to further, potentially harmful interventions. In addition, 
negative results can give false reassurance. 
 
PM), http://www.aafp.org/online/en/home/publications/news/news- 
now/health-of-the-public/20111012psascreenrec.html. 
23. Id. 
24. Id. 
25. Richard J. Ablin, The Great Prostate Mistake, N.Y. Times, March 10, 
2010, at A27. 
26. Sandip M. Prasad et al., 2008 US Preventive Services Task Force 
Recommendations and Prostate Cancer Screening Rates, 307 JAMA 1692, 
1693 (2012). 
27. Telephone Interview with Jonathan Katz, M.D. (June 18, 2012). 
28. Average Doctor Visit Grows -- by 32 Seconds over 10 Years, World 
News & Nursing Rpt. (Sept. 1, 2007), http://www.asrn.org/journal-
world-news-nursing-report/7-average-doctor-visit-grows-by-32-seconds-over-
10-years.html.  
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Furthermore, patients and doctors tend to make different choices 
depending on the way statistical estimates of potential medical benefit 
are presented. While “a fifty-five-year-old man may, for instance, be 
interested in an 18 percent reduction in the relative risk of dying from 
colorectal cancer” with screening, he may be “more reluctant if told that 
screening implies an absolute risk reduction of only 0.014 percent a 
year.”29 Alternatively, he may “consider that the likelihood of not dying 
from colorectal cancer is 99.34 percent if you are screened and 99.20 
percent if you are not screened. Unless the doctor is willing to solve this 
information dilemma by using a simple paternalistic reminder such as, 
‘take the test, it is good for you,’ many preventive interventions seem 
too complex to suit the model of opportunistic health promotion in the 
general practitioner’s office.”30 
Considering the controversy swirling around PSA testing, it is  
outrageous that so many patients are subjected to it without their 
knowledge or consent. It is difficult, however, to document what  
percentage of patients is given the opportunity to make an informed 
choice before engaging in PSA testing. In 2010, researchers in the United 
Kingdom reported that only about a third of 106 men given a PSA test 
were aware of such basic facts as the goals of the test and the likelihood 
that it would lead to further testing.31 The report does not address 
whether the men were even told that a PSA had been ordered. It appears 
that men who do undergo an informational process are significantly less 
likely to express interest in PSA testing than those who were not given 
that opportunity.32 
A 1999 study in the United States found that one-third of patients at 
a primary care clinic were “unaware that they had received a screening 
PSA test, and among patients who were aware of having the test done, 
fewer than half recalled having a discussion about the associated benefits 
and risks.”33 The study further found that “most men did not know that 
treatment of localized prostate cancer has not been shown to increase 
survival and can lead to impotence and incontinence. The results indicate 
that, in most cases, the process of verbal informed consent between 
patients and health care providers was either ineffective or not done.”34  
 
29. Getz et al., supra note 5, at 499. 
30. Id.  
31. See Ashok R. Gunawardene & Mark Kitchen, Informed Consent for PSA 
Testing: An Outpatient Audit, 8 Int’l J. Surgery 577, 577 (2010).  
32. Andrew M.D. Wolf et al., The Impact of Informed Consent on Patient 
Interest in Prostate-Specific Antigen Screening, 156 Archives Internal 
Med. 1333, 1334 (1996). 
33. Daniel G. Federman et al., Informed Consent for PSA Screening: Does It 
Happen?, 2 Effective Clinical Prac. 152, 154 (1999). 
34. Id. at 155. 
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In short, PSA testing is a medical intervention on which reasonable 
minds can differ but which certainly fulfills the ethical criteria for 
requiring informed consent. Taking the test might save your life. Taking 
the test might lead to unnecessary treatment with significant and 
irreversible side effects. Medical organizations urge that physicians 
discuss the pros and cons of PSA testing with individual patients.  Yet 
significant percentages of patients are given the test without their 
consent because the test is opportunistic.  
III. Newborn screening 
State-mandated newborn screening began in the 1960s by targeting 
phenylketonuria (PKU).35 In some places, newborn screening is still 
referred to as “the PKU test.”36 In this genetic condition, a baby is born 
without the ability to break down the amino acid phenylalanine.37 Babies 
with PKU become irreversibly developmentally delayed on a normal 
diet, but they can progress normally if put on a strict diet that excludes 
phenylalanine.38 Because early intervention (before symptoms become 
apparent) is crucial and an effective intervention exists, PKU remains 
the “poster child” of a successful newborn screening program.39  
For some time after PKU screening began, other tests were slowly 
added. In the past, screening for each new condition required an entirely 
different test and different lab equipment. Given the tremendous expense 
of testing all newborns in a state and the relatively small number of 
children identified, each new test had to surmount a rigorous test of its 
own in order to be adopted. This slow progression “changed with the 
invention of tandem mass spectrometry, which allows for ‘multiplex 
testing’ on the same blood sample for many conditions at once.”40 Mass 
spectrometry has “allowed for unprecedented expansion of newborn 
screening.”41 The DNA chip, “already in use in the private sector, will 
soon make possible additional, exponential expansion of [newborn 
 
35. See Simone Van Der Burg & Marcel Verweij, Maintaining Trust in 
Newborn Screening: Compliance and Informed Consent in the Netherlands, 
42 Hastings Ctr. Rep. 41, 41 (2012).  
36. See id. 
37. Nat’l Inst. of Health, Phenylketonuria, Medline Plus, http://www.nlm. 
nih.gov/medlineplus/ency/article/001166.htm (last updated June 17, 
2011). 
38. See id. 
39. See id. 
40. Dena S. Davis, Genetic Dilemmas: Reproductive Technology, 
Parental Choices, and Children’s Futures 113 (2d ed. 2010). 
41. Id. at 113-14. 
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screening programs].”42 Whereas mass spectrometry “measures levels of 
various metabolites in the blood, the microchips will screen directly for 
the genetic basis of various disorders.”43 The National Human Genome 
Research Institute is currently working to reduce the cost of sequencing 
an entire human genome to $1,000 by 2014,44 from a cost of just under 
$8,000 in 2012.45 
The explosive expansion of new conditions to be screened is  
controversial. When each condition had to be justified on its own, new 
screens were added sparingly. Now, there are many pressures to expand 
screening and no clear criteria for adding new conditions. Rachel Grob 
identifies a number of factors contributing to the rapid expansion of 
newborn screening, including “technological innovation, political oppor-
tunity, interstate rivalries, and competitive pressure on state programs 
from private laboratories.”46 Advocacy groups, often propelled by families 
whose own child might have been saved from the consequences of a rare 
disease if timely screening had been available, push hard to add “their” 
disease to the screening panel.47 Interestingly, parents of children with 
disorders for which there is currently no medical intervention, such as 
Fragile X, are equally enthusiastic about routine screening.48 
Underlying the debate is the fact that almost all newborn screening 
is done without the informed consent of the parents. In many states, 
parents can theoretically refuse screening, but because they are rarely 
told of it beforehand, or told only in very vague terms, this right to 
refuse is close to meaningless.49 A test given without parental consent 
can only ethically be defended on the grounds of potential benefit to 
 
42. Rachel Grob, Testing Baby: The Transformation of Newborn 
Screening, Parenting, and Policy Making 8 (Rima D. Apple et al. 
eds., 2011). 
43. Davis, supra note 40, at 114. 
44. Id. 
45. Omar McCrimmon, New NIH/NHGRI Grants to Harness Nanoscale 
Technologies to Cut DNA Sequencing Costs, Nat’l Human Genome Res. 
Inst. (Sept. 14, 2012), http://www.nih.gov/news/health/ 
sep2012/nhgri-14.htm.  
46. Grob, supra note 42, at 3. 
47. See Lainie Friedman Ross & Darrel J. Waggoner, Parents: Critical 
Stakeholders in Expanding Newborn Screening, 161 J. Pediatrics 385, 386 
(2012). 
48. See President’s Council on Bioethics, The Changing Moral Focus 
of Newborn Screening: An Ethical Analysis by the President’s 
Council on Bioethics 62 (2008), available at 
http://bioethics.georgetown.edu/pcbe/reports/newborn_screening/Newbo 
rn%20Screening%20for%20the%20web.pdf. 
49. See Rachel Grob, Parenting in the Genomic Age: The ‘Cursed Blessing’ of 
Newborn Screening, 25 New Genetics & Soc’y 159, 159, 163 (2006). 
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children, backed up by strong evidence. PKU screening fulfills those 
requirements (assuming that the state follows up with parental educa-
tion and ensures access to the expensive diet), but screening for other 
conditions may not. Screening for cystic fibrosis, for example, has been 
controversial because not everyone agrees that there is a medical 
advantage to early, presymptomatic diagnosis. However, studies show 
that early diagnosis of cystic fibrosis prevents malnutrition and improves 
children’s growth and cognitive function.50  
Screening also has the potential for harm, as can be seen in screening 
for Fragile X Syndrome, the most common form of inherited intellectual 
disability. Although Fragile X can have devastating developmental and 
intellectual consequences, one-third to one-half of all females with the 
mutation are intellectually normal. Identifying those children could cause 
unnecessary anxiety in parents or lead them to have mistakenly low 
expectations of what their daughters can achieve.51   
All large screening programs result in a fair number of false positives 
that need to be followed by more specific diagnostic tests. Upon  
additional testing, the result is often a “false alarm.” Parents, however, have 
been shown to continue to feel anxious and to relate differently to their 
baby even once they have been reassured about the outcome.52  
Screening ought to result in a demonstrable benefit, but there is  
disagreement on what kinds of “benefits” count.53 Saving a child from the 
devastating effects of PKU is a wonderful benefit. But by what rationale 
should we screen for disorders for which there is no known medical 
intervention? Even if the infant itself does not benefit directly, one could 
argue that there are benefits to the family or to society as a whole. 
Society, for example, could benefit from knowing more about the incidence 
of a disease. Of course, this is a research question, and normally we do not 
allow research on children without parental permission. Parents could 
benefit from having a heritable disease diagnosed early, before embarking 
on another pregnancy. Parents (and arguably the child) could also benefit 
by being spared a “diagnostic odyssey” when the child does become 
symptomatic. 
 
50. Rebecca L. Koscik et al., Cognitive Function of Children with Cystic 
Fibrosis: Deleterious Effects of Early Malnutrition, 113 Pediatrics 1549, 
1549 (2004). 
51. Donald B. Bailey, Jr. et al., Ethical, Legal, and Social Concerns About 
Expanded Newborn Screening: Fragile X Syndrome as a Prototype for 
Emerging Issues, 121 Pediatrics e693, e696 (2008). 
52. See Elizabeth A. Gurian et al., Expanded Newborn Screening for 
Biochemical Disorders: The Effect of a False-Positive Result, 117 
Pediatrics 1915, 1919-20 (2006). 
53. Donald B. Bailey, Jr. et al., Changing Perspectives on the Benefits of 
Newborn Screening, 12 Mental Retardation & Developmental 
Disabilities Research Rev. 270, 271 (2006).  
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From some perspectives, there are few, if any, ethical limits on new-
born screening. Duane Alexander, former Director of the National 
Institute of Child Health and Human Development, considers the principle 
that one should screen only for disorders for which a treatment exists as 
an “outmoded” dogma.54 Alexander and others call for the development of 
multiplex screening that would screen newborns for every medically 
significant genetic marker.55 Rather than demanding a rationale for adding 
a screen, every marker is presumptively “screenable” in the absence of a 
good reason to exclude it.56 The President’s Commission on Bioethics 
expressed its discomfort with this methodology by terming the practice 
“newborn profiling.”57 In the 1990s, a number of reports argued that the 
only justification for newborn screening was the possibility of substantial 
benefit to the child. In the twenty-first century, that perspective seems to 
be losing out to a wider and not well-delineated notion of “benefit” and of 
appropriate beneficiaries.58 
For recessive genetic diseases such as cystic fibrosis, a false positive 
finding may result in a finding that the baby, while healthy, is a carrier. 
Knowledge of carrier status can result in inappropriate parental anxiety 
and serve to reveal a parent’s genetic make-up—all without consent. In 
this way, newborn screening can act as a kind of proxy genetic testing of 
the parents. Children who are carriers of a recessive gene will never get 
sick themselves, so the test does not benefit them. But it does act as 
unconsented, unsolicited genetic testing of parents59 and shares with 
parents information about the child’s genetic make-up that violates the 
child’s future privacy. If parents are known not to be carriers of the 
condition for which their child is a carrier, anxiety about paternity can 
ensue even though it is possible for the child to have a spontaneous 
mutation that neither parent carries.60  
Newborn screening can also warn parents of the genetic risks they 
run with their next pregnancy, but without consent, such information is 
a mixed blessing. Rachel Grob argues that “[t]he state’s delivery of 
unsolicited genetic risk information to women of child-bearing age is a 
real threat to reproductive autonomy, yet a sustained dialogue about 
 
54. Duane Alexander & Peter C. van Dyck, A Vision of the Future of Newborn 
Screening, 117 Pediatrics S350, S352 (2006). 
55. Id. at S350-54. 
56. See id. at S352. 
57. See President’s Council on Bioethics, supra note 48, at 56. 
58. Bailey, Jr. et al., supra note 53, at 271. 
59. See Grob, supra note 49, at 162.  
60. Anthony J.F. Griffiths et al., An Introduction to Genetic 
Analysis (7th ed. 2000), available at http://www.ncbi.nlm.nih.gov/ 
books/NBK21897/. 
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this consequence of universal screening is sorely lacking amid the willy-
nilly rush to expand state programmes.”61 
When newborn screening was purely for PKU, one could at least make 
the argument that no parent should risk a baby’s health by refusing the 
PKU test, although that argument does not obviate the need for parental 
consent. As time went on, the number of tests exploded and began to 
include conditions that were not responsive to treatment (e.g., Duschennes 
muscular dystrophy) or were collected for research purposes only. This is 
why I label these screens as opportunistic—one begins with a well-
established test that the subject expects or that has some sort of rationale, 
and then piggybacks additional tests onto the same sample. Of course, 
more tests should equal more need for consent, especially when the 
purpose shifts from clinical to research, but in fact all the pressures push 
in the other direction.  
The actual incidence of finding the disease when one screens a general 
population is relatively low. For example, the incidence of PKU varies 
greatly across the world; however, in the United States, one of 15,000 
infants born every year has the disease.62 It is one thing to push an 
informational folder into the hand of every distracted new parent, but 
should we really ask a health professional to spend ten or fifteen minutes 
explaining PKU to each parent when that discussion will prove largely 
irrelevant 14,999 times out of 15,000? With the relative ease of adding one 
more test onto the panel, informed consent becomes more difficult to 
support.  
One way to encourage more meaningful parental involvement in  
newborn screening (and perhaps to alleviate the anxiety of a false positive 
result) is to give information during the prenatal period when parents 
have time to assimilate it and to ask questions. The New England Region-
al Genetics Group, for example, produces a simple, informative brochure 
that can be customized for the different states and made available in 
many languages.63 The brochure does not, however, tell parents that they 
have the right to refuse screening, nor does it inform them that not every 
test produces “actionable” information relevant to their baby’s health.64 
Currently, Internet information could be an important resource for 
new and expectant parents. The Internet is an especially appropriate 
venue for public health education such as information about newborn 
screening, which delivers generally applicable information and typically 
 
61. Grob, supra note 49, at 162-63. 
62. See Nat’l PKU Alliance, PKU Facts, Nat’l PKU Alliance, 
http://www.npkua.org/index.php/pku-facts (last visited Jan. 13, 2013). 
63. New England Newborn Screening Brochure, New England Relational 
Genetics Group, Inc., http://www.nergg.org/nbsbrochures.php (last 
visited Jan. 17, 2013). 
64. Id. 
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does not require “personal messaging.”65 Araia and Potter analyzed two 
sets of guidelines developed in the United States (in 2000 and 2006) and 
identified fourteen “messages” that the guidelines recommended be 
communicated to parents about newborn screening.66 Tellingly, none of 
the fourteen involved parental consent. Using the fourteen recommenda-
tions as well as their own addition of informed consent, Araia and Potter 
conducted a systematic search of public websites of newborn screening 
programs in the United States and Canada in 2008. 67 Sixteen percent of 
US sites and none of the Canadian sites included information about 
policies for storage and secondary (research) use of samples. 68  Seventy-
eight percent of the US sites but only 11 percent of the Canadian sites 
presented information about parental consent or refusal. 69 Over 80 percent 
of the sites presented the benefits of newborn screening, while fewer than 
60 percent included information about the risks (e.g., false positives).70 
Another way for parents to receive information about newborn 
screening during the prenatal period is to read about it in the plethora of 
popular pregnancy manuals available today. A nonscientific sampling of 
what is available at a local Barnes & Nobles yielded mixed results. The 
three manuals for sale all mentioned newborn screening. The most 
disappointing was The Mommy Docs’ Ultimate Guide to Pregnancy and 
Birth, which provided four sentences couched entirely in the passive 
mood as if parents were totally disengaged from the process: “Your baby 
will be screened for a panel of diseases before you leave the hospital . . . . 
The results of these tests will be sent to your pediatrician within a 
month.”71  
Great Expectations: Your All-in-One Resource for Pregnancy and 
Childbirth did somewhat better, mentioning that the array of tests 
differed by state and ending with “[i]f you would like to know more 
about the tests, don’t be shy about asking your baby’s pediatrician for 
more information.”72 I was disappointed that the hugely popular What to 
Expect When You’re Expecting, nearly in its 600th week on the New 
 
65. Mollyann Brodie et al., Health Information, the Internet, and the Digital 
Divide, 19 Health Affairs 255, 262 (2000). 
66. Makda H. Araia & Beth K. Potter, Newborn Screening Education on the 
Internet: A Content Analysis of North American Newborn Screening 
Program Websites, 2 J. Community Genetics 127, 129 (2011).  
67. Id. at 128-29.  
68. Id. at 129. 
69. Id. at 129-30. 
70. Id. at 129. 
71. Yvonne Bohn et al., The Mommy Docs’ Ultimate Guide to 
Pregnancy and Birth 287 (2011). 
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York Times Book Review best seller list,73 is extremely vague, talking 
about life-threatening diseases without naming any and stating that 
“early diagnosis and intervention can make a tremendous difference in 
the prognosis,” without giving any idea of what kind of prognosis that 
might be.74 What to Expect does refer parents to useful websites for more 
information, including one that informs the reader whether her state 
screens for the conditions recommended by the March of Dimes.75 I had 
to go online to satisfy my curiosity about Our Bodies, Ourselves: 
Pregnancy and Birth, part of the series that began in 1971 with the 
explicit goal of empowering women through information.76 Not surpris-
ingly, Our Bodies, Ourselves gave the most detailed information, 
including the fact that some states include HIV screening in their panel 
of tests.77 It was the only book to tell women that they could refuse 
screening or even request additional tests.78 None of the books mentioned 
that newborn screening could pick up information with no health 
consequences, such as carrier status for recessive genetic diseases. 
In addition to screening newborns without parental consent, some 
states have also retained the dried blood spots (preserved from the 
newborns’ heelsticks) and used them for research purposes, again 
without consent. Michigan, for example, now has “almost four million 
stored blood spots potentially available for research representing state 
birth cohorts from 1984 to the present.”79 These deidentified blood spots 
were used in ten studies without the consent of the parents.80 This 
research use of existing tissue samples is considered acceptable under the 
federal guidelines governing research with human subjects.81 In February 
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2010, however, in response to a lawsuit initiated by parents, the State of 
Texas was forced to incinerate millions of cached and deidentified blood 
spots collected since 2002; parents successfully claimed that retaining the 
samples without their knowledge or consent constituted an illegal search 
and seizure.82 In 2009, Texas began a program allowing parents to opt 
out of retention.83 
In Michigan, the BioTrust for Health was inaugurated in 2009.84 The 
formation of the BioTrust changed the paradigm for use of blood spots in 
the state. Before the BioTrust, the spots were collected primarily for 
screening, stored in large part for purposes of quality control, and used (in 
deidentified form) only “incidentally” for research.85 After the inauguration 
of the BioTrust, research became one of the primary goals.86 The Michigan 
Department of Community Health Institutional Review Board (IRB) 
determined that parental permission was required before stored samples 
could be used for research.87 Although deidentifying samples addressed 
parental privacy concerns, other concerns also existed, including the 
possibility that the state would use samples in research not consonant 
with individual parents’ values.88 It will be interesting to see if and how 
this more rigorous standard for parental consent to retain and use blood 
samples for research purposes will change the standards for consenting to 
screening alone. The IRB wondered if “the explicit request to consent to 
research might make new parents question why they were not asked for 
their consent to take blood from their child in the first place.”89 
In sum, the ease with which new screens can be added threatens pa-
rental rights to be aware of and consent to the medical tests conducted 
on their children and the research their children take part in. Lack of 
consent is doubly sad because parents would overwhelmingly grant 
consent if they were asked. In Maryland, where consent is required, a 
survey found that only 27 out of approximately 50,000 mothers declined 
screening but that more than half of those mothers thought it important 
that they be asked.90  
82. Ann Waldo, The Texas Newborn Bloodspot Saga has Reached a Sad—and 
Preventable—Conclusion, Genomics L. Rep. (Mar. 16, 2010), 
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IV. Noninvasive Prenatal Diagnosis 
Finally, I will consider noninvasive testing for Down Syndrome (DS) 
based on cell-free fetal nucleic acids. DS is a chromosomal abnormality 
consisting of an extra chromosome on the twenty-first pair, often termed 
Trisomy 21.91 DS is one of the most common genetic birth defects.92 
Children with DS often have physiological problems requiring surgery, 
such as malformed hearts or digestive system blockages.93 The majority 
of people with DS have hearing and vision problems.94 They always have 
distinguishing facial characteristics and some degree of intellectual 
disability.95 Although prenatal screening and testing for DS was one of 
the earliest available tests, knowing that a fetus has DS does not reveal 
how severe the condition will be.96 Some children with DS graduate from 
high school, hold down jobs, live semi-independently, and even marry. 
Others are much more severely affected.97 
The standard practice for screening and testing pregnant women for 
fetal chromosomal abnormalities such as DS is a mix of noninvasive and 
invasive screenings and tests throughout the first and second trimesters.98 
An array of screening tools based on maternal blood samples provides 
each pregnant woman with an individual risk assessment, but they are not 
diagnostic and will not detect all chromosomal abnormalities.99 Invasive 
testing—chorionic villus sampling (CVS) or amniocentesis—is extremely 
accurate, but carries a small but significant risk of miscarriage.100  
Ironically, while the risk of trisomy increases with maternal age,101 
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maternal age is also associated with lessened fertility; it is precisely those 
women with the highest risk of chromosomal abnormality who can least 
afford to lose a wanted pregnancy. Invasive testing is also time-consuming 
and labor-intensive. Therefore, an early, noninvasive, highly accurate test 
for DS is one of the “holy grails” of prenatal diagnosis.102 
In October 2011, the company Sequenom announced that it was  
releasing a test that detects DS through cell-free fetal DNA circulating 
in maternal blood during the first trimester of pregnancy.103 Natera, a 
company that already offers noninvasive fetal paternity testing, is also 
conducting trials for noninvasive testing for DS.104 Sequenom claims that 
its test “is aimed at the estimated 750,000 pregnancies at high risk for 
Down Syndrome annually in the U.S.,”105 but as the cost of testing 
comes down, there is no reason to reserve it only for pregnancies at high 
risk for DS. Although Sequenom’s test is currently limited to DS and is 
less accurate for other types of chromosomal abnormalities, it has a 98.6 
percent success rate in accurately identifying DS pregnancies, with a 
0.20 percent false-positive rate.106 While the study authors concluded 
that conventional invasive testing should follow this test,107 the hope for 
the near future is that invasive tests will be rendered unnecessary in 
most cases.108 
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There are, of course, enormous emotional and ethical issues attached 
to prenatal diagnosis. While an oft-heard statistic is that 90 percent of 
pregnancies diagnosed with DS are terminated, that figure reflects a 
population that had already agreed to go ahead with testing, presumably 
with at least some openness to termination. Others choose not to test 
because they would not terminate. When the gold standard for detection 
of DS is an invasive test (i.e., CVS or amniocentesis), informed consent 
is a sine qua non. The risk of miscarriage makes consent crucial, as each 
woman will evaluate and balance the risks in an individual way. But, it 
obviously would be unthinkable to perform CVS or amniocentesis 
without consent because it is an invasive, stand-alone procedure that 
cannot be piggybacked onto something else. A woman undergoing an 
amniocentesis knows she is having an amniocentesis. Marteau and 
colleagues report that, in one group of over 200 women, 29 percent who 
had an Alpha Fetaprotein screening test denied having had it (presuma-
bly because they had not been aware of being tested), whereas all of the 
women who underwent amniocentesis appeared to have given truly 
informed consent.109 “Confronted with a long needle or a transvaginal 
probe, few, if any, women will undergo either procedure without under-
standing that something serious is happening.”110 Thus, CVS and 
amniocentesis are the focus of thoughtful, often anguished decision-
making. Weighing the risk of having a baby with DS versus the risk of 
losing a healthy fetus forces couples to think about DS and what a child 
with it would mean for their family.  
I am not extolling anguish for its own sake—there is enough anguish 
in the world already—and I think that a decisive test for DS that is 
noninvasive and free of risk is a wonderful thing. It is excellent that 
women will be able to focus on the question of testing for DS without 
the risk of miscarriage. However, I worry that this will become another 
opportunistic test often performed without informed consent.  
It also appears that many women receive prenatal screening (the 
blood tests used within the first and second trimesters of pregnancy to 
estimate a woman’s risk of having a baby with certain genetic defects) 
without proper consent.111 In addition to Marteau’s study, a German 
study found that 16 percent of women either had not given consent or 
could not remember giving consent.112 A French study found that nearly 
half the women who had undergone prenatal screening were “unin-
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formed” about the procedure.113 But it is difficult to know what to make 
of this. Pregnancy is a busy time, and prenatal care involves many tests 
to protect and monitor the health of the mother and her fetus. Thus, it 
is possible that many women understood and consented to a test and 
then forgot about it when the results were of no concern. However, a 
recent study of American obstetricians found that a surprisingly large 
number of pregnant women age thirty-five and over refused screening, 
ranging from almost 20 percent of women in the West and Northeast, to 
more than 30 percent in the South.114 That result suggests that women 
did make a decision and felt comfortable going against “routine.”115 
Scholars differ on whether noninvasive prenatal diagnosis (NIPD) for 
DS will lead to more or less robust informed consent. De Jong and 
colleagues argue that NIPD testing does not present a greater challenge 
to ensuring a proper consent process116:  
[I]n current practice information, counselling [sic] and consent are  
often inadequate[] . . . . However, as long as NIPD testing will be  
offered for the same range of abnormalities as in the present[]  
approach to prenatal screening, there is no reason to assume that 
these problems will be larger than they already are.117  
Greely worries that without the lengthy counseling necessitated by an 
invasive procedure, “how can we ensure that parents understand what 
they are consenting to? Already some who get results from blood-based 
screening . . . are shocked to learn they ever agreed to the test.”118 In 
other words, so-called “informed consent” was not consent at all. Van 
den Heuvel and colleagues conducted the first study to assess how 
practitioners view the consent process for noninvasive as opposed to 
invasive testing; they concluded that practitioners may view them 
differently, and that “[t]here is potential for the introduction of NIPD to 
undermine women making informed choices in the context of prenatal 
diagnostic testing for conditions like DS.”119 
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Ravitsky, however, looks forward to the time when counselors will be 
able to devote more time to discussing “the possible results of the test—
and the alternatives open to women and their families—rather than 
spend[ing] a substantial amount of time and effort discussing the risk 
inherent in the test.”120 She believes that NIPD would promote autono-
mous decision making by shifting the focus where it belongs.121 And 
Deborah Driscoll, a geneticist and chair of the University of Pennsylva-
nia, Perelman School of Medicine’s Department of Obstetrics and 
Gynecology, where the new test was rolled out in August 2012, said,  
“I think one of the concerns that some geneticists and ethicists have is 
that we want to be sure that women give informed consent.”122 She 
states that “this [should] not [be] viewed as a routine laboratory test,” 
and that “[e]very physician or counselor that offers this [should] explain[] 
to the patient what the test is for, what are the limitations for the test 
and what it can potentially disclose.”123 
At issue here is something I will call the “crossroads effect.” At pre-
sent, a fairly common attitude appears to be that maternal serum 
screening (the so-called “triple” and “quadruple” tests offered in the first 
and second trimesters)124 does not require a robust consent process. 
Although the American College of Obstetricians and Gynecologists, for 
example, directs healthcare providers to make extensive information 
about screening tests available to patients “so that they can make 
informed decisions,”125 the empirical studies cited elsewhere in this essay 
show that the reality can be quite different. This may well be, at least in 
part, because no final decisions will be acted upon in response to the 
screening test alone. A positive screen becomes a crossroads moment at 
which a woman must decide whether or not to undergo invasive diagnos-
tic testing. Because only about 5 percent of pregnancies will have a 
positive screen result necessitating further decisions,126 the attitude of 
many busy practitioners may well mirror the attitude I posited earlier 
about consent for PSA testing. That is the moment when routine 
changes into individualized decision making.  
I fear that screening without informed consent will become testing 
without informed consent in a fairly seamless way. The threat to 
autonomy comes from opportunistic testing combined with pressures of 
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time and money and extruded through the trend toward routinization 
that seems pervasive in medicine.127 Once routinized, clinicians will 
portray NIPD tests, and women will experience them, as a routine and 
normal part of prenatal care.128 “This may lead to normalization of 
uptake, ranging from a rather thoughtless uptake to women feeling 
socially pressurized to be tested.”129  
In sum, noninvasive prenatal diagnosis for DS can be a boon to  
women’s autonomy, allowing them to think clearly about motherhood and 
disability without the distractions of an invasive and minimally risky test. 
It will also allow women who choose to terminate to do so in the first 
trimester when it is safer, easier, and cheaper. But that advance in 
autonomy could be offset if testing is not accompanied by the  
opportunity for thoughtful informed consent. 
V. Conclusion 
The bioethics movement was born as a full-throated defense of  
patient empowerment. Respect for persons meant respect for the 
voluntary, informed choice of the competent patient, the better to 
support personal autonomy. The challenges in the twentieth century 
were lack of information and a paternalistic medical profession. In the 
twenty-first century, the challenge to autonomy may be a combination 
of opportunistic testing, new technology, and lack of time.  
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